Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4
- PMID: 1692094
- DOI: 10.1093/jnci/82.10.848
Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4
Abstract
Although it is well established that angiogenesis is essential to tumor development, no human protein with high specificity and efficacy for prevention of angiogenesis has been characterized. In a previous study, we demonstrated that recombinant platelet factor 4 (rPF 4) inhibited angiogenesis in the chicken chorioallantoic membrane. In the present study, we have extended that finding to the use of recombinant human platelet factor 4 (rHuPF 4) to inhibit solid tumor growth in the mouse. rHuPF 4 effectively suppressed the growth of the B16-F10 murine melanoma in syngeneic C57BL/6J hosts and prevented the growth of primary tumors of both B16-F10 murine melanoma and HCT 116 human colon carcinoma in semisyngeneic CByB6F1/J female athymic nude mice. These two transformed cell lines were completely insensitive to rHuPF 4 in vitro at levels (50 micrograms/mL) that extensively inhibit normal endothelial cell proliferation. The migration of human endothelial cells was also inhibited at these concentrations of rHuPF 4, suggesting a second mechanism by which rHuPF 4 may modulate capillary development. The observed antitumor effects of rHuPF 4 might be due to the inhibition of angiogenesis. This finding could have implications for the development of novel therapeutic approaches to angiogenic diseases. Alternative, and possibly concurrent, mechanisms of the rHuPF 4 antitumor effect include lymphokine-activated killer cell activation and the induction of other cytokines.
Similar articles
-
Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity.Cancer Res. 1991 Apr 15;51(8):2077-83. Cancer Res. 1991. PMID: 1706960
-
Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4.J Natl Cancer Inst. 1995 Feb 15;87(4):304-9. doi: 10.1093/jnci/87.4.304. J Natl Cancer Inst. 1995. PMID: 7707422
-
Combination of Caspy2 and IP-10 gene therapy significantly improves therapeutic efficacy against murine malignant neoplasm growth and metastasis.Hum Gene Ther. 2012 Aug;23(8):837-46. doi: 10.1089/hum.2011.136. Epub 2012 Jul 20. Hum Gene Ther. 2012. PMID: 22548488
-
Recombinant platelet factor 4: a therapeutic, anti-neoplastic chimera?Semin Thromb Hemost. 2010 Jul;36(5):558-69. doi: 10.1055/s-0030-1255450. Epub 2010 Jul 14. Semin Thromb Hemost. 2010. PMID: 20632253 Review.
-
Explanations for reduced tumor proliferative capacity with age.Exp Gerontol. 1992 Sep-Dec;27(5-6):551-8. doi: 10.1016/0531-5565(92)90009-o. Exp Gerontol. 1992. PMID: 1426087 Review.
Cited by
-
Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology.J Hematol Oncol. 2013 Jun 24;6:42. doi: 10.1186/1756-8722-6-42. J Hematol Oncol. 2013. PMID: 23800319 Free PMC article. Review.
-
Anti-angiogenic treatment strategies for malignant brain tumors.J Neurooncol. 2000 Oct-Nov;50(1-2):149-63. doi: 10.1023/a:1006487412567. J Neurooncol. 2000. PMID: 11245274 Review.
-
Antiangiogenic gene therapy of cancer: recent developments.J Transl Med. 2004 Jun 25;2(1):22. doi: 10.1186/1479-5876-2-22. J Transl Med. 2004. PMID: 15219236 Free PMC article.
-
Judah Folkman, a pioneer in the study of angiogenesis.Angiogenesis. 2008;11(1):3-10. doi: 10.1007/s10456-008-9092-6. Epub 2008 Feb 5. Angiogenesis. 2008. PMID: 18247146 Free PMC article.
-
Angiostatic, tumor inflammatory and anti-tumor effects of CXCL4(47-70) and CXCL4L1(47-70) in an EGF-dependent breast cancer model.Oncotarget. 2014 Nov 15;5(21):10916-33. doi: 10.18632/oncotarget.2538. Oncotarget. 2014. PMID: 25373734 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous